ArticleZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2026
[Association of sodium-glucose linked transporter 2 inhibitors with functional outcomes at discharge in diabetic patients with acute ischemic stroke].
Article in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04487340 (Computer-based Online Database of Acute Stroke Patients for Stroke Management Quality Evaluation), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Computer-based Online Database of Acute Stroke Patients for Stroke Management Quality Evaluation
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the association between the use of sodium-glucose linked transporter 2 (SGLT2) inhibitors and functional outcomes at discharge in diabetic patients with acute ischemic stroke (AIS).
methodsA retrospective cohort study was conducted using data from the Acute Stroke Patients for Stroke Management Quality Evaluation online database (CASE-Ⅱ, NCT04487340) for patients admitted between January 2022 and November 2024. Diabetic patients with AIS were categorized as SGLT2 inhibitor users or non-users (control group). Patients' functional outcomes were assessed using the modified Rankin Scale (mRS) score. Propensity score matching (PSM) was performed in a 1∶2 ratio. Multivariate logistic regression models were used to assess the association between SGLT2 inhibitor use and outcomes. Stratified analyses were performed based on pre-existing diabetes versus newly diagnosed diabetes during the hospitalization and the impact of long-term and short-term use of SGLT2 inhibitors on patients' functional outcomes at discharge was analyzed.
resultsThe study included 9220 patients (mean age 67±11 years; 39.38% female), of whom 1915 (20.77%) were SGLT2 inhibitor users. There were 1912 cases in the user group and 3683 cases in the non-user group after PSM. Before PSM, the proportion of patients with an mRS score 0-2 at discharge was significantly higher in the SGLT2 inhibitor group than that in the control group (79.84%
conclusionsAmong diabetic patients with AIS, SGLT2 inhibitor use is independently associated with better functional outcomes at discharge, showing a potential benefit for short-term neurological recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.